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Fig 1. Dermatomyositis, clinical images. Erosive erythem-
atous patches on chest. Inset shows erythematous papules
on interphalangeal joints (Gottron sign) and periungual
erythema.
Fig 2. Dermatomyositis, histopathology. Punch biopsy of
poikilodermatous erosive plaque on the shoulder shows
an interface dermatitis with mild spongiosis, epidermal
necrosis, and subepidermal vesicle formation. (Hematox-
ylin-eosin stain; original magnification 320.)
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Dermatomyositis associated with capecitabine
in the setting of malignancy
To the Editor: Dermatomyositis (DM) is a rare
autoimmune condition characterized by cutaneous
and muscle inflammation. In addition to malignancy,
24 medications have also been implicated in trig-
gering DM.1 Herein, we report a new case of DM
triggered by oral capecitabine, a prodrug of
5-fluorouracil (5-FU), in the setting of underlying
malignancy.
A 76-year-old man with a recent diagnosis of
metastatic gastric adenocarcinoma presented with
diffuse rash and muscle weakness 2 weeks after
receiving a cycle of carboplatin with capecitabine
(1 g orally twice daily). He had previously received 1
infusion of carboplatin alone 3 weeks before this
cycle without any adverse effects. On examination,
the patient was noted to have poikilodermatous
plaques with shallow erosions scattered in a
V-distribution on his upper chest and upper back
(Fig 1). His hands contained erythematous, scaly
papules symmetrically distributed over the metacar-
pophalangeal and interphalangeal joints (Gottron
papules) as well as periungual erythema (Fig 1).
Muscle strength testing revealed severe proximal
weakness of the lower extremities, leading to an
inability to ambulate. No electromyography (EMG)
was conducted in this case.
Open access under CC BY-NC-ND license.Laboratory analysis revealed an elevated creatine
kinase (CK) of 2630 U/L, aldolase of 10.9 U/L,
erythrocyte sedimentation rate (ESR) of 66 mm/hr,
C-reactive protein (CRP) of 1.46 mg/dL, and lactate
dehydrogenase (LDH) of 294 IU/L. Results were
negative for antinuclear antibody (ANA), anti-Jo, and
anti-centromere antibodies. A punch biopsy of the
shoulder revealed an interface dermatitis with mild
spongiosis, epidermal necrosis, and subepidermal
vesicle formation (Fig 2). Thus, clinical, laboratory,
and histopathologic findings were consistent with a
diagnosis of DM. Capecitabine was discontinued and
oral prednisone was initiated, resulting in reduction
in CK level to 698 U/L and improved strength and
ability to ambulate. The patient was discharged
home. Due to the oncologic need to treat the
patient’s gastric adenocarcinoma, he was restarted
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later. After reinitiation of capecitabine 1 g twice daily,
the patient was readmitted to the hospital with a CK
of 938 U/L. This time, he experienced a flare of his
rash on his chest and back, accompanied by severely
worsened proximal lower extremity weakness and
dysphagia. Upon admission, capecitabine was with-
held, and both intravenous methylprednisone
(80 mg per day) and intravenous immunoglobulin
(2 g/kg over 2 days) were initiated; his condition
improved.
We report a novel case in which rechallenge
with capecitabine resulted in a DM flare following
interval corticosteroid therapy. DM has previously
been controversially associated with 5-FU, in that 2
cases have been previously reported, but it remains
unclear if this was due to the 5-FU or was incidental
to the malignancy.2,3 Our patient underwent
rechallenge of capecitabine, with relapse of cuta-
neous and muscular symptoms, definitively impli-
cating this 5-FU prodrug as triggering DM in the
setting of underlying malignancy. We hypothesize
that DM triggered by capecitabine and, likely, 5-FU
may require the hypermetabolic state of cancer and
the release of tumor antigens. However, it may be
challenging to distinguish whether medication or
underlying malignancy is the inciting cause of DM,
in that both may result in an inflammatory myop-
athy with similar pathophysiology and cutaneous
findings. Researchers have found that statins are
associated with the production of autoantibodies
against targets related to muscle differentiation and
regeneration.4 It is possible that capecitabine may
directly lead to an inflammatory response causing
DM in a similar way as statins. Patients with cancertreated with capecitabine who present with skin
rash and muscle weakness should be promptly
evaluated for potential DM.
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